Skip to main content
BiogenPatent grant

Biogen was granted a patent for combination treatments for multiple sclerosis.

Source: Autobound Signal API · 76 signals tracked for Biogen · updated

Get Biogen's live signals in Claude or ChatGPT, or by API

AskWhat changed at Biogen this week? Use Autobound signals for biogen.com.

What happened

In October 2026 Biogen patented a drug combination for treating multiple sclerosis and other autoimmune diseases in clinical care.

Source

patents.google.comOct 13, 2026

US patent US12758525

Combination treatment methods of multiple sclerosis

Abstract

The present disclosure provides combination therapies for treating an autoimmune disease in a subject in need thereof. The methods comprise administering to the subject an effective amount of a BTK inhibitor in combination with an effective amount of a fumaric acid ester (FAE). The autoimmune disease can be treated include, for example, multiple sclerosis (MS), lupus, rheumatoid arthritis (RA), Pemphigus Vugaris (PV), neuromyelitis optica (NMO), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), anti-NMDA receptor encephalitis, or Sjogren's disease.

patents.google.com/patent/US12758525Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Oct 13, 2026
Inventors
4
Patent number
US12758525
Assignee
BIOGEN MA INC.

The full record

From the Signal API record

People

  • Michael Joseph PalteInventor
  • Brian T. HopkinsInventor
  • Matthew P. ScaramozzaInventor
  • Michael Christian MingueneauInventor
  • Alex PellerinInventor
  • Chelsea R. Parker HarpInventor

Details

Primary CPC class
A61K 31/4015
USPTO assignee
BIOGEN MA INC.
What the invention does
A treatment approach that pairs a BTK-blocking medicine with a fumaric acid ester to help control abnormal immune activity.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • BTK inhibitors
  • fumaric acid esters
  • autoimmune disease treatment

Extraction

Detected
Oct 14, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Biogen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/934b63f8-bacf-5dea-917e-dbc8058de5ae returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.

{
  "signal_id": "934b63f8-bacf-5dea-917e-dbc8058de5ae",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-10-14T15:10:07+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "cpc": [
      {
        "code": "A61K 31/4015"
      },
      {
        "code": "A61K 31/225"
      },
      {
        "code": "A61K 31/4545"
      },
      {
        "code": "A61K 31/4985"
      },
      {
        "code": "A61K 31/506"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In October 2026 Biogen patented a drug combination for treating multiple sclerosis and other autoimmune diseases in clinical care.",
    "summary": "Biogen was granted a patent for combination treatments for multiple sclerosis.",
    "event_at": "2026-10-13",
    "inventors": [
      {
        "name": "Michael Joseph Palte",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/michael-palte-84703722"
      },
      {
        "name": "Brian T. Hopkins",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/brian-hopkins-aa159312"
      },
      {
        "name": "Matthew P. Scaramozza",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Michael Christian Mingueneau",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/mingueneau"
      },
      {
        "name": "Alex Pellerin",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Chelsea R. Parker Harp",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/chelsea-r-parker-harp-71392435"
      },
      {
        "name": "Catherine Barbey",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/catherinebarbey"
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-10-13",
    "source_url": "https://patents.google.com/patent/US12758525",
    "cpc_primary": {
      "code": "A61K 31/4015"
    },
    "patent_title": "Combination treatment methods of multiple sclerosis",
    "patent_number": "US12758525",
    "uspto_assignee": "BIOGEN MA INC.",
    "patent_abstract": "The present disclosure provides combination therapies for treating an autoimmune disease in a subject in need thereof. The methods comprise administering to the subject an effective amount of a BTK inhibitor in combination with an effective amount of a fumaric acid ester (FAE). The autoimmune disease can be treated include, for example, multiple sclerosis (MS), lupus, rheumatoid arthritis (RA), Pemphigus Vugaris (PV), neuromyelitis optica (NMO), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), anti-NMDA receptor encephalitis, or Sjogren's disease.",
    "precision_class": "structural",
    "invention_explanation": "A treatment approach that pairs a BTK-blocking medicine with a fumaric acid ester to help control abnormal immune activity.",
    "technologies_mentioned": [
      "BTK inhibitors",
      "fumaric acid esters",
      "autoimmune disease treatment"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.